Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
J Hypertens
    April 2024
  1. SASAKI N, Maeda R, Ozono R, Yoshimura K, et al
    Differences in the impact of newly diagnosed type 2 diabetes on cardiovascular mortality between normotensive and hypertensive individuals.
    J Hypertens. 2024;42:610-619.
    >> Share

  2. BARCELLOS PAM, Dall'Agnol A, Sandi GM, Remonti LR, et al
    Dietary approach for the treatment of arterial hypertension in patients with diabetes mellitus.
    J Hypertens. 2024;42:583-593.
    >> Share

  3. WANG R, Zhao J, Li L, Huo Y, et al
    Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
    J Hypertens. 2024;42:727-734.
    >> Share

    March 2024
  4. KOLLIAS A, Kyriakoulis KG, Komnianou A, Stathopoulou P, et al
    Prognostic value of home versus ambulatory blood pressure monitoring: a systematic review and meta-analysis of outcome studies.
    J Hypertens. 2024;42:385-392.
    >> Share

    February 2024
  5. TARKKONEN A, Fickweiler W, Eriksson M, Sun JK, et al
    Retinal artery to vein ratio is associated with cerebral microbleeds in individuals with type 1 diabetes.
    J Hypertens. 2024 Feb 28. doi: 10.1097/HJH.0000000000003690.
    >> Share

  6. ZHANG L, Wang W, Gong J, Wang X, et al
    Development, validation, and clinical utility of a risk prediction model for recurrent preeclampsia.
    J Hypertens. 2024;42:236-243.
    >> Share

    January 2024

  7. Reply to 'Diabetes and orthostatic hypotension: are all patients treated equal?': Erratum.
    J Hypertens. 2024;42:195.
    >> Share

    December 2023
  8. SASAGAWA Y, Inoue Y, Futagami K, Nakamura T, et al
    Application of deep neural survival networks to the development of risk prediction models for diabetes mellitus, hypertension, and dyslipidemia.
    J Hypertens. 2023 Dec 14. doi: 10.1097/HJH.0000000000003626.
    >> Share

  9. CRUZ-LOPEZ EO, Ye D, Stolk DG, Clahsen-van Groningen MC, et al
    Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects.
    J Hypertens. 2023 Dec 11. doi: 10.1097/HJH.0000000000003633.
    >> Share

    October 2023
  10. RIJAL A, Adhikari TB, Dhakal S, Maagaard M, et al
    Effects of adding exercise to usual care on blood pressure in patients with hypertension, type 2 diabetes, or cardiovascular disease: a systematic review with meta-analysis and trial sequential analysis.
    J Hypertens. 2023 Oct 6. doi: 10.1097/HJH.0000000000003589.
    >> Share

    August 2023
  11. ABUSHAMAT LA, Enge D, Fujiwara T, Schafer M, et al
    Obesity dominates early effects on cardiac structure and arterial stiffness in people with type 2 diabetes.
    J Hypertens. 2023 Aug 18. doi: 10.1097/HJH.0000000000003534.
    >> Share

    July 2023
  12. BERETTA MV, Hoffmeinster M, da Costa Rodrigues T
    Reply to 'Diabetes and orthostatic hypotension: are all patients treated equal?'.
    J Hypertens. 2023;41:1219-1220.
    >> Share

  13. CUSPIDI C, Gherbesi E, Tadic M
    Diabetes and orthostatic hypotension: are all patients created equal?
    J Hypertens. 2023;41:1217-1218.
    >> Share

    April 2023
  14. GAO ZX, Wei QC, Shu TT, Li ST, et al
    Kir4.1 deletion prevents salt-sensitive hypertension in early streptozotocin-induced diabetic mice via Na+-Cl- cotransporter in the distal convoluted tubule.
    J Hypertens. 2023 Apr 5. doi: 10.1097/HJH.0000000000003419.
    >> Share

    March 2023
  15. XIONG S, Yin S, Deng W, Zhao Y, et al
    Predictive value of liver fibrosis scores in cardiovascular diseases among hypertensive population.
    J Hypertens. 2023 Mar 2. doi: 10.1097/HJH.0000000000003394.
    >> Share

  16. KOBAYASHI A, Fujihara K, Yamada MH, Sato T, et al
    Combined effects of blood pressure and glycemic status on risk of heart failure: a population-based study.
    J Hypertens. 2023;41:470-475.
    >> Share

    February 2023
  17. CARDOSO CRL, Leite NC, Salles GF
    Relative prognostic importance of aortic and brachial blood pressures for cardiovascular and mortality outcomes in patients with resistant hypertension and diabetes: a two cohorts prospective study.
    J Hypertens. 2023 Feb 2. doi: 10.1097/HJH.0000000000003387.
    >> Share

  18. KAWADA T
    Cardiovascular disease risk in patients with type 2 diabetes and hypertension.
    J Hypertens. 2023;41:365.
    >> Share

  19. AGARWAL R, Ruilope LM, Ruiz-Hurtado G, Haller H, et al
    Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
    J Hypertens. 2023;41:295-302.
    >> Share

  20. ISAKSSON GL, Nielsen LH, Palarasah Y, Jensen DM, et al
    Urine excretion of C3dg and sC5b-9 coincide with proteinuria and development of preeclampsia in pregnant women with type-1 diabetes.
    J Hypertens. 2023;41:223-232.
    >> Share

  21. ZHOU TL, Reulen JPH, Van Der Staaij H, Stehouwer CDA, et al
    Cardiovagal baroreflex sensitivity, blood pressure and blood pressure variability - the Maastricht study.
    J Hypertens. 2023;41:254-261.
    >> Share

    December 2022
  22. BERETTA MV, Milan VB, Hoffmeister MC, Rodrigues TC, et al
    Orthostatic hypotension, falls and in-hospital mortality among elderly patients with and without type 2 diabetes.
    J Hypertens. 2022 Dec 23. doi: 10.1097/HJH.0000000000003338.
    >> Share

  23. TEO YH, Chia AZQ, Teo YN, Chong EY, et al
    The impact of sodium-glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials.
    J Hypertens. 2022;40:2353-2372.
    >> Share

    November 2022
  24. JIN S, Reesink KD, Kroon AA, de Galan B, et al
    Complement factors D and C3 cross-sectionally associate with arterial stiffness, but not independently of metabolic risk factors: The Maastricht Study.
    J Hypertens. 2022;40:2161-2170.
    >> Share

    October 2022
  25. HELLEPUTTE S, Spronck B, Sharman JE, Van Bortel L, et al
    Central blood pressure estimation in type 1 diabetes: impact and implications of peripheral calibration method.
    J Hypertens. 2022 Oct 10. pii: 00004872-990000000-00126.
    >> Share

    August 2022
  26. ARAUJO-CASTRO M, Paja Fano M, Gonzalez Boillos M, Pla Peris B, et al
    Predictive model of hypertension resolution after adrenalectomy in primary aldosteronism: the SPAIN-ALDO score.
    J Hypertens. 2022 Aug 24. pii: 00004872-990000000-00101.
    >> Share

  27. MARCON D, Tagetti A, Piona C, Giontella A, et al
    Markers of subclinical vascular damage in young adults with type 1 diabetes mellitus: the role of central blood pressure.
    J Hypertens. 2022 Aug 23. pii: 00004872-990000000-00096.
    >> Share

  28. HATA S, Ushigome E, Yoshimura T, Takegami M, et al
    Maximum home blood pressure and cardiovascular outcomes in patients with type 2 diabetes: KAMOGAWA-HBP study.
    J Hypertens. 2022 Aug 19. pii: 00004872-990000000-00088.
    >> Share

  29. BARDEN AE, Shinde S, Phillips M, Beilin LJ, et al
    Mediators of inflammation resolution and vasoactive eicosanoids in gestational diabetes and preeclampsia.
    J Hypertens. 2022 Aug 9. pii: 00004872-990000000-00076.
    >> Share

    July 2022
  30. BIRUKOV A, Glintborg D, Schulze MB, Jensen TK, et al
    Elevated blood pressure in pregnant women with gestational diabetes according to the WHO criteria: importance of overweight.
    J Hypertens. 2022 Jul 6. pii: 00004872-990000000-00028.
    >> Share

    June 2022
  31. UAGBOE AA, Ogboye A, Munee MM, Rahman KJ, et al
    LEVERAGING TECHNOLOGY TO SUPPORT PEOPLE LIVING WITH HYPERTENSION AND DIABETES DURING THE COVID-19 PANDEMIC.
    J Hypertens. 2022;40.
    >> Share

  32. TARKKONEN A, Fickweiler W, Sun J, Thorn L, et al
    CHANGES IN RETINAL VESSEL DIAMETER ARE ASSOCIATED WITH CEREBRAL MICROBLEEDS IN NEUROLOGICALLY ASYMPTOMATIC INDIVIDUALS WITH TYPE 1 DIABETES.
    J Hypertens. 2022;40.
    >> Share

  33. BARRAGAN ACP, Leiva VG, Espejel LD
    REACHING OF THERAPEUTICS GOALS IN PATIENTS WITH HYPERTENSION AND DIABETES MELLITUS. DO MULTIPLE THERAPY WORKS?
    J Hypertens. 2022;40.
    >> Share

  34. DOAN L
    EFFICACY OF SGLT2I IN ACUTE DECOMPENSATED HEART FAILURE WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  35. PATOULIAS D, Katsimardou A, Boulmpou A, Imprialos K, et al
    META-ANALYSIS OF THE EFFECT OF DUAL GIP AND GLP-1 RECEPTOR AGONISTS ON BLOOD PRESSURE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  36. PAFFER MT, Paffer PT, Paffer T, Castro C, et al
    ARTERIAL STIFFNESS ASSESSMENT IN DIABETIC PATIENTS IN A CARDIOLOGY CLINIC.
    J Hypertens. 2022;40.
    >> Share

  37. MANUKYAN M, Falkovskaya A, Mordovin V, Zyubanova I, et al
    SYSTEMIC VASCULAR RESISTANCE AS A PREDICTOR OF ANTIHYPERTENSIVE EFFICIENCY OF RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION AND TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  38. BOSCH A, Poglitsch M, Kannenkeril D, Ott C, et al
    ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE.
    J Hypertens. 2022;40.
    >> Share

  39. FALKOVSKAYA A, Mordovin V, Pekarskiy S, Manukyan M, et al
    FEATURES OF CHANGES IN THE LEVELS OF MATRIX METALLOPROTEINASES AND THEIR INHIBITORS IN DIABETIC PATIENTS WITH RESISTANT HYPERTENSION AFTER RENAL DENERVATION.
    J Hypertens. 2022;40.
    >> Share

  40. FALKOVSKAYA A, Mordovin V, Pekarskiy S, Manukyan M, et al
    THE EFFECT OF RENAL DENERVATION ON CEREBRAL BLOOD FLOW IN DIABETIC PATIENTS WITH RESISTANT HYPERTENSION.
    J Hypertens. 2022;40.
    >> Share

  41. FALKOVSKAYA A, Mordovin V, Pekarskiy S, Manukyan M, et al
    THE EFFECT OF RENAL DENERVATION ON PERIPHERAL AND CEREBRAL VASOREACTIVITY IN PATIENTS WITH RESISTANT HYPERTENSION AND TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  42. MANUKYAN M, Falkovskaya A, Mordovin V, Zyubanova I, et al
    LEPTIN AS A PREDICTOR OF CARDIOPROTECTIVE EFFICIENCY OF RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION AND TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  43. ANYFANTI P, Nikolaidou B, Gavriilaki E, Triantafyllou A, et al
    MICRO- AND MACROVASCULAR ALTERATIONS IN RHEUMATOID ARTHRITIS COMPARED TO TYPE 2 DIABETES MELLITUS: EVIDENCE OF SIMILAR DEGREE OF ORGAN DAMAGE.
    J Hypertens. 2022;40.
    >> Share

  44. SHORIKOVA D, Shorikov E, Shorikov P, Ismael O, et al
    POLYMORPHISMS NOS3-T-786C IN MACROANGIOPATHIES IN PATIENTS WITH COMBINED HYPERTENSION AND TYPE DIABETES MELLITUS 2.
    J Hypertens. 2022;40.
    >> Share

  45. ZERVAKIS S, Marketou M, Plevritaki A, Kontaraki J, et al
    MICRORNA PROFILE ANALYSIS IN PERICORONARY ADIPOSE TISSUE OF DIABETIC PATIENTS WITH SIGNIFICANT CORONARY ARTERY DISEASE.
    J Hypertens. 2022;40.
    >> Share

  46. GEORGIANOU E, Markakis K, Georgianos P, Zografou I, et al
    PREVALENCE AND CONTROL OF HYPERTENSION IN DIABETIC PATIENTS WITH VERSUS WITHOUT CHRONIC KIDNEY DISEASE.
    J Hypertens. 2022;40.
    >> Share

  47. MIRADA M, Pessana F, Acuna MIR, Ramirez A, et al
    ARTERIAL HYPERTENSION (HT) IS ONE OF THE MOST PREDICTIVE RISK FACTORS FOR TYPE 2 DIABETES (DM2). THE FINDRISC IS VALIDATED FOR THE EARLY DETECTION OF SUFFERING FROM DM2.
    J Hypertens. 2022;40.
    >> Share

  48. RODERO EMA, Esmeral LPM, Mogollon LGR, Charris MA, et al
    ASSOCIATION BETWEEN THE TIME OF EVOLUTION AND LIFESTYLES WITH ADHERENCE TO TREATMENT FOR DIABETES MELLITUS. BARRANQUILLA COLOMBIA.
    J Hypertens. 2022;40.
    >> Share

  49. RODERO EMA, Esmeral LPM, Contrera ME, Charris MA, et al
    LEVEL OF ADHERENCE TO THE PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENT OF PATIENTS WITH DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  50. PAPAVASILEIOU M, Aravantinos D, Karamanou A, Moustakas G, et al
    PROGNOSTIC VALUE OF THE GLYCOSYLATED HEMOGLOBIN TO THE MACE IN HYPERTENSIVE NON DIABETIC PATIENTS.
    J Hypertens. 2022;40.
    >> Share

  51. LOPEZ EOC, Ren L, Uijl E, Clahsen-Van Groningen MC, et al
    BLOOD PRESSURE-INDEPENDENT RENOPROTECTION IN DIABETIC RATS TREATED WITH SMALL INTERFERING RNA TARGETING LIVER ANGIOTENSINOGEN.
    J Hypertens. 2022;40.
    >> Share

  52. DOAN L
    SGLT2I - A POTENTIAL ANTIHYPERTENSIVE AGENT IN HYPERTENSION PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  53. GEORGIANOU E, Markakis K, Georgianos P, Zografou I, et al
    THE ASSOCIATION OF EGFR AND ALBUMINURIA WITH SYSTOLIC HYPERTENSION IN PATIENTS WITH DIABETES.
    J Hypertens. 2022;40.
    >> Share

  54. HELLEPUTTE S, Spronck B, Sharman J, Bortel LV, et al
    CENTRAL BLOOD PRESSURE ESTIMATION IN TYPE 1 DIABETES: IMPACT OF PERIPHERAL BLOOD PRESSURE CALIBRATION APPROACH.
    J Hypertens. 2022;40.
    >> Share

  55. HILL J, Faber M, De Villiers A, Mulabisano T, et al
    DEVELOPMENT OF TEXT-MESSAGING TO SUPPORT THE SOUTH AFRICAN DIABETES PREVENTION PROGRAM.
    J Hypertens. 2022;40.
    >> Share

  56. HILL J, Yako Y, Rusike C, Toni S, et al
    APPLICABILITY OF THE SOUTH AFRICAN DIABETES PREVENTION PROGRAMME IN THE EASTERN CAPE PROVINCE OF SOUTH AFRICA: A STUDY PROTOCOL.
    J Hypertens. 2022;40.
    >> Share

  57. LEBEDEV D, Lyasnikova E, Vasilyeva E, Sitnikova M, et al
    PREDICTORS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH EMPAGLIFLOZIN.
    J Hypertens. 2022;40.
    >> Share

  58. MARCON D, Tagetti A, Giontella A, Bortolotti S, et al
    SUBCLINICAL VASCULAR DAMAGE IN YOUNG ADULTS WITH TYPE 1 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  59. NELAJ E, Kecaj I, Gjata M, Tase M, et al
    ATHEROSCLEROSIS AND INCIPIENT NEPHROPATHY IN DIABETIC PATIENTS.
    J Hypertens. 2022;40.
    >> Share

  60. NIKOLAIDOU B, Triantafyllou A, Anyfanti P, Gavriilaki E, et al
    STUDY OF EARLY RETINAL CHANGES IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  61. PATOULIAS D, Katsimardou A, Stavropoulos K, Imprialos K, et al
    CARDIOVASCULAR OUTCOMES WITH FINERENONE ACCORDING TO STATUS OF GLYCEMIA AT BASELINE AND PRIOR TREATMENT WITH NEWER ANTIDIABETICS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  62. PATOULIAS D, Toumpourleka M, Katsimardou A, Zografou I, et al
    BENEFICIAL EFFECT OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS ON RIGHT VENTRICULAR SYSTOLIC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PILOT, OBSERVATIONAL STUDY.
    J Hypertens. 2022;40.
    >> Share

  63. PATOULIAS D, Siskos F, Katsimardou A, Imprialos K, et al
    META-ANALYSIS ADDRESSING THE EFFECT OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS ON FLOW-MEDIATED DILATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  64. PEER N, Nguyen K, Hill J, Kengne AP, et al
    PREVALENCE OF DIABETES AND PREDIABETES AMONG ADULTS WITH HIV IN AFRICA: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    J Hypertens. 2022;40.
    >> Share

  65. RAMIREZ AJ, Pessana F, Sanchez MJ, Sanchez RA, et al
    CANAGLIFLOZIN IS MORE EFFECTIVE THAN PERINDOPRIL TO IMPROVE RENAL HYPERFILTRATION AND URINARY ALBUMIN EXCRETION IN TYPE 2 DIABETES PATIENTS.
    J Hypertens. 2022;40.
    >> Share

  66. MARTINEZ F, Calderon JM, Sauri I, Fernandez A, et al
    REAL WORLD IMPACT OF BLOOD PRESSURE CHANGES ON MORBIDITY AND MORTALITY IN TYPE 2 DIABETES.
    J Hypertens. 2022;40.
    >> Share

  67. RUS H, Poinareanu I, Bobescu E
    EFFECT OF EMPAGLIFOZIN ON 24-HOUR BLOOD PRESSURE, BRACHYAL ENDOTHELIAL DYSFUNCTON, AND LEFT VENTRICULAR DIASTOLIC FUNCTION, IN PATIENTS WITH TYPE-2 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  68. SEMIANIV M, Semianiv I
    THE RISK OF COMBINED PATHOLOGY OF DIABETES MELLITUS AND TUBERCULOSIS.
    J Hypertens. 2022;40.
    >> Share

  69. BOUNTZONA I, Kollias A, Kyriakoulis K, Destounis A, et al
    NIGHT-TIME BLOOD PRESSURE ASSESSED BY HOME VS. AMBULATORY MONITORING IN ADULTS WITH TYPE 2 DIABETES: ASSOCIATION WITH PRECLINICAL TARGET ORGAN DAMAGE.
    J Hypertens. 2022;40.
    >> Share

  70. MENTI A, Kollias A, Bountzona I, Konstantakopoulos S, et al
    NIGHT-TIME BLOOD PRESSURE IN DIABETES TYPE-1 ASSESSED BY HOME VS. AMBULATORY MONITORING: A PILOT STUDY.
    J Hypertens. 2022;40.
    >> Share

  71. WANG Q, Tian L, Sun R, Qi M, et al
    EFFECTS OF SGLT-2 INHIBITORS ON 24H AMBULATORY BLOOD PRESSURE IN PATIENTS WITH TYPE 2 DIABETIC AND HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    J Hypertens. 2022;40.
    >> Share

  72. CHALAKOVA T, Tsochev K, Yotov Y, Bocheva Y, et al
    ARTERIAL HYPERTENSION IN PATIENTS WITH LONG DURATION TYPE 1 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

  73. ZEMMOUCHI S
    THE SPECIFICS OF HEMODIALYSIS IN DIABETICS. EASTERN ALGERIAN EXPERIENCE.
    J Hypertens. 2022;40.
    >> Share

  74. ZHURAVLYOVA L, Rogachova T, Sokolnikova N, Filonenko M, et al
    THE EFFECT OF DAPAGLIFLOZIN ON THE LEVEL OF SYSTOLIC BLOOD PRESSURE AND GLYCEMIC CONTROL IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES.
    J Hypertens. 2022;40.
    >> Share

  75. MONTEALEGRE L, Amador E, Pulido T, Rebolledo R, et al
    FACTORS THAT INFLUENCE THE SURVIVAL RATE IN PATIENTS WITH COVID-19 WITH A PREVIOUS DIAGNOSIS OF HYPERTENSION AND/OR DIABETES: A SYSTEMATIC REVIEW.
    J Hypertens. 2022;40.
    >> Share

  76. IOANNIDIS A, Pechlevanis A, Fragkiskou A, Asmani F, et al
    SELF-REPORTED CHANGE IN (UN)HEALTHY BEHAVIOURS OF PATIENTS WITH CARDIOVASCULAR DISEASES DURING THE SECOND COVID-19 LOCKDOWN IN NORTHERN GREECE: FOCUS ON DIABETES.
    J Hypertens. 2022;40.
    >> Share

  77. JAIN R, Hosseini J, Shoghli R
    COVID19 INFECTION IN CORONARY ARTERY DISEASE WITH DIABETES AND HYPERTENSION IN VALVULAR SURGERY PATIENTS IN TERTIARY HEART CENTRE.
    J Hypertens. 2022;40.
    >> Share

  78. PATOULIAS D, Katsimardou A, Toumpourleka M, Boulmpou A, et al
    EFFECT OF SGLT-2 INHIBITORS ON THE RISK FOR ANGINA IN PATIENTS WITH OR WITHOUT TYPE 2 DIABETES MELLITUS: A META-ANALYSIS.
    J Hypertens. 2022;40.
    >> Share

  79. PATOULIAS D, Katsimardou A, Imprialos K, Stavropoulos K, et al
    GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT DECREASE THE RISK FOR CORONARY REVASCULARIZATION IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS.
    J Hypertens. 2022;40.
    >> Share

  80. PATOULIAS D, Katsimardou A, Sviggou A, Kordalis V, et al
    MAJOR ADVERSE EVENTS WITH THE USE OF FINERENONE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS.
    J Hypertens. 2022;40.
    >> Share

  81. BORTOLOTTI S, Cattazzo F, Tagetti A, Marcon D, et al
    CARDIOVASCULAR RISK FACTORS IN TYPE 1 DIABETES MELLITUS: ANY DIFFERENCE BETWEEN ADOLESCENTS AND YOUNG ADULTS FOR SUBCLINICAL ATHEROSCLEROSIS?
    J Hypertens. 2022;40.
    >> Share

  82. NIELSEN S, Nyvad J, Christensen KL, Poulsen PL, et al
    OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH INCREASED CORONARY CALCIFICATION AND ARTERIAL STIFFNESS IN PATIENTS WTH DIABETIC NEPHROPATHY.
    J Hypertens. 2022;40.
    >> Share

  83. SECIN AAR, Moreno FJA, Martinez TR, Rivero JB, et al
    PREVALENCE OF TARGET ORGAN DAMAGE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN IBERICAN STUDY.
    J Hypertens. 2022;40.
    >> Share

  84. SILVA AF, Cruz RC, Albuquerque NLS, Silva VM, et al
    METHODS AND NUMBER OF BLOOD PRESSURE ASSESSMENTS USED TO ASSESS BLOOD PRESSURE VARIABILITY IN INDIVIDUALS WITH DIABETES.
    J Hypertens. 2022;40.
    >> Share

  85. SILVA S, Sousa AC, Sousa AL, Vitorino P, et al
    BEHAVIOR OF PRESSURE VARIABILITY IN PATIENTS WITH ARTERIAL HYPERTENSION AND DIABETES MELLITUS WITH OR WITHOUT INSULIN USE AND THE INFLUENCE OF THE NUTRITIONAL STATE IN BRAZIL.
    J Hypertens. 2022;40.
    >> Share

  86. SOUSA AC, Magalhaes FG, Silva SB, Simeoni AR, et al
    ASSOCIATION OF SHORT-TERM BLOOD PRESSURE VARIABILITY WITH DIABETES IN HYPERTENSIVE INDIVIDUALS.
    J Hypertens. 2022;40.
    >> Share

  87. BEREZIN A, Fushtey I, Berezin A
    UTILITY OF IRISIN AND APELIN IN PREDICTION OF HEART FAILURE PHENOTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS.
    J Hypertens. 2022;40.
    >> Share

  88. NIKOLAIDOU B, Anyfanti P, Gavriilaki E, Dolgyras P, et al
    DIABETIC STATUS AND NIGHT-TIME SYSTOLIC BLOOD PRESSURE PREDICT EARLY MYOCARDIAL DAMAGE IN NEWLY DIAGNOSED DIABETES MELLITUS TYPE 2 PATIENTS AS THIS IS DEPICTED BY GALECTIN-3 LEVELS.
    J Hypertens. 2022;40.
    >> Share

  89. BENDIAB NT, Bouanane S, Baba Ahmed FZ
    EVALUATION OF PLASMA HOMOCYSTEINE LEVELS AND ERYTHROCYTE ANTIOXIDANT ENZYMATIC ACTIVITIES IN TYPE 2 DIABETICS WITH ARTERIAL HYPERTENSION.
    J Hypertens. 2022;40.
    >> Share

  90. SHAMANNA P, Joshi S, Shah L, Dharmalingam M, et al
    CORRELATION OF DIABETES REMISSION WITH REDUCTIONS IN BLOOD PRESSURE AND CARDIOVASCULAR RISK SCORES: RESULTS OF SIX MONTHS OF RANDOMISED TRIAL WITH DIGITAL TWIN TECHNOLOGY.
    J Hypertens. 2022;40.
    >> Share

  91. THANH HN, Trong KHP, Huu AN, Xuan GNT, et al
    PREVALENCE OF HYPERTENSION AND DISTRIBUTION OF BODY MASS INDEX LEVELS AMONG OLDER ADULTS WITH TYPE 2 DIABETES MELLITUS IN VIETNAM: A MULTICENTRE STUDY.
    J Hypertens. 2022;40.
    >> Share

  92. KUZIOR A, Hernandez-Lazaro A, De Leon-Durango R, Rios-Gomez C, et al
    INITIATION OF EMPAGLIFLOZIN THERAPY IS ASSOCIATED WITH A CLINICALLY RELEVANT DECREASE IN BLOOD PRESSURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND UNCONTROLLED HYPERTENSION.
    J Hypertens. 2022;40.
    >> Share

  93. ALBA-LINARES JJ, Fernandez-Perez R, Ponce-Zanon F, Garcia-Carbonell N, et al
    MATERNAL OBESITY AND GESTATIONAL DIABETES ARE ASSOCIATED WITH DNA METHYLATION ALTERATIONS IN THE OFFSPRING THROUGHOUT THE FIRST YEAR OF LIFE.
    J Hypertens. 2022;40.
    >> Share

  94. NORDB OP, Landolt L, Eikrem O, Scherer A, et al
    COMPARATIVE TRANSCRIPTOMIC ANALYSIS IDENTIFIES EPITHELIAL-MESENCHYMAL TRANSITION AND INFLAMMATION AS COMMON PATHOGENETIC MECHANISMS IN HYPERTENSIVE AND DIABETIC NEPHROPATHY.
    J Hypertens. 2022;40.
    >> Share

  95. JENKINS S, Gupta P, Khunti K, Cross A, et al
    THE EFFECT OF BIOFEEDBACK ON HYPERTENSION AND DIABETES: PRELIMINARY RESULTS FROM A SYSTEMATIC REVIEW.
    J Hypertens. 2022;40.
    >> Share

  96. TIMASHEVA Y, Balkhiyarova Z, Prokopenko I
    DISENTANGLING THE SHARED HERITABILITY OF THE PREDISPOSITION TO HYPERTENSION AND TYPE 2 DIABETES.
    J Hypertens. 2022;40.
    >> Share

  97. SANZ-GOMEZ M, Vega-Martin E, Gonzalez-Moreno D, Pizzamiglio C, et al
    FINERENONE PREVENTS RENAL AND VASCULAR DAMAGE IN A NOVEL MODEL OF TYPE 1 DIABETES MELLITUS.
    J Hypertens. 2022;40.
    >> Share

    March 2022
  98. KAWADA T
    Comment on 'Sodium-glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease'.
    J Hypertens. 2022;40:624.
    >> Share

    February 2022
  99. GENG Q, Hou F, Zhang Y, Wang Z, et al
    Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis.
    J Hypertens. 2022 Feb 25. pii: 00004872-900000000-96482.
    >> Share

  100. VAN DER LINDEN EL, Meeks KAC, Klipstein-Grobusch K, Bahendeka S, et al
    Hypertension determinants among Ghanaians differ according to location of residence: the Research on Obesity and Diabetes among African Migrants study.
    J Hypertens. 2022 Feb 11. pii: 00004872-900000000-96494.
    >> Share

  101. BRADY TM, Horst G, Appel LJ, Khoury PR, et al
    Dietary sodium intake and sodium load is associated with arterial stiffness in children and young adults.
    J Hypertens. 2022;40:292-299.
    >> Share

    January 2022
  102. WANG Y
    Stage 1 hypertension and risk of cardiovascular disease mortality in United States adults with or without diabetes.
    J Hypertens. 2022 Jan 31. pii: 00004872-900000000-96504.
    >> Share

    December 2021
  103. SIAFI E, Andrikou I, Konstantinidis D, Kakouri N, et al
    Fatty liver index and hypertension-mediated organ damage in never-treated hypertensive patients without diabetes mellitus.
    J Hypertens. 2021;39:2470-2477.
    >> Share

    November 2021
  104. GIUDICI A, Palombo C, Kozakova M, Morizzo C, et al
    Noninvasive carotid pressure-diameter loops to identify viscoelastic properties in ageing, hypertension and type 2 diabetes.
    J Hypertens. 2021;39:2307-2317.
    >> Share

    September 2021
  105. NOLDE JM, Frost S, Kannenkeril D, Lugo-Gavidia LM, et al
    Capillary vascular density in the retina of hypertensive patients is associated with a non-dipping pattern independent of mean ambulatory blood pressure.
    J Hypertens. 2021;39:1826-1834.
    >> Share

    August 2021
  106. THANGARAJ SS, Oxlund CS, Fonseca MPD, Svenningsen P, et al
    The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-[gamma] and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension.
    J Hypertens. 2021 Aug 23. pii: 00004872-900000000-96579.
    >> Share

    July 2021
  107. CARRA MC, Fessi S, Detzen L, Darnaud C, et al
    Self-reported periodontal health and incident hypertension: longitudinal evidence from the NutriNet-Sante e-cohort.
    J Hypertens. 2021 Jul 13. pii: 00004872-900000000-96626.
    >> Share

    November 2020
  108. MURRAY HORWITZ ME, Rodriguez MI, Dissanayake M, Carmichael SL, et al
    Postpartum health risks among women with hypertensive disorders of pregnancy, California 2008-2012.
    J Hypertens. 2020 Nov 18. doi: 10.1097/HJH.0000000000002711.
    >> Share

    August 2020
  109. LIU X, Song Q, Wu S, Zhou W, et al
    Prediabetes and risk for myocardial infarction by hypertension status in a Chinese population: a prospective cohort study.
    J Hypertens. 2020 Aug 29. doi: 10.1097/HJH.0000000000002607.
    >> Share

    July 2020
  110. SAVOIA C, De Ciuceis C, Paini A, Carletti R, et al
    Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients.
    J Hypertens. 2020 Jul 27. doi: 10.1097/HJH.0000000000002595.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016